PRMT5 inhibitors and uses thereof

1. A compound of formula (V):

or a pharmaceutically acceptable salt thereof,

wherein:

X 1 , X 2 , X 3 and X 4 are independently selected from the group consisting of N and CH, provided that at least one of X 2 , X 3 , and X 4 is not N;

R 1 is hydrogen;

L is —O— or —N(R)—;

each R is independently hydrogen or optionally substituted C 1-6 aliphatic;

L is a bond;

Cy is an optionally substituted 5,6-bicyclic heteroaryl or an optionally substituted 6,6-bicyclic heteroaryl, wherein the bicyclic heteroaryl has 1-4 ring heteroatoms independently selected from nitrogen, oxygen and sulfur, and wherein the point of attachment is on the 6-membered ring;

each of R 5 , R 6 , R 7 , and R 8 is hydrogen;

each R x is independently selected from the group consisting of halo, —CN, optionally substituted aliphatic, —OR′, and —N(R″) 2 ;

R′ is hydrogen or optionally substituted aliphatic;

each R″ is independently hydrogen or optionally substituted aliphatic, or two R″ are taken together with their intervening atoms to form a heterocyclic ring; and

n is 0, 1, or 2;

wherein each instance of aliphatic is independently an alkyl, alkenyl, alkynyl, cycloalkyl, or cycloalkenyl group.

2. The compound of claim 1 , wherein n is 0.

3. The compound of claim 1 , wherein Cy is optionally substituted indazole, optionally substituted quinoline, optionally substituted benzimidazole, optionally substituted benzothiazole, optionally substituted deazapurine, optionally substituted indole, optionally substituted purine, optionally substituted pyrazolopyridine, optionally substituted pyrrolopyridine, optionally substituted pyrrolopyrimidine, or optionally substituted imidazopyridine.

4. The compound of claim 1 , wherein the compound is selected from the group consisting of:

and pharmaceutically acceptable salts thereof.

5. A pharmaceutical composition comprising a compound of claim 1 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

6. A method of treating a PRMT5-mediated disorder, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt thereof

wherein the PRMT5-mediated disorder is cancer, a metabolic syndrome, or a blood disorder;

wherein the cancer is a hematopoietic cancer, lung cancer, prostate cancer, melanoma, or pancreatic cancer;

wherein the metabolic disorder is diabetes or obesity; and

wherein the blood disorder is a hemoglobinopathy.

7. The method of claim 6 , wherein the PRMT5-mediated disorder is cancer, and wherein the cancer is a hematopoietic cancer, lung cancer, prostate cancer, melanoma, or pancreatic cancer.

8. The method of claim 6 , wherein the PRMT5-mediated disorder is a metabolic disorder, and wherein the metabolic disorder is diabetes or obesity.

9. The method of claim 6 , wherein the PRMT5-mediated disorder is a blood disorder, and wherein the blood disorder is a hemoglobinopathy.

10. The method of claim 9 , wherein the hemoglobinopathy is sickle cell anemia or β-thalessemia.

11. The compound of claim 1 , wherein the compound is of formula (V-a):

or a pharmaceutically acceptable salt thereof.

12. The compound of claim 1 , wherein the compound is of formula (V-b):

or a pharmaceutically acceptable salt thereof.

13. The compound of claim 1 , wherein the compound is of formula (VI):

or a pharmaceutically acceptable salt thereof.

14. The compound of claim 1 , wherein the compound is of formula (VII):

or a pharmaceutically acceptable salt thereof.

15. The compound of claim 1 , wherein the compound is of formula (VIII):

or a pharmaceutically acceptable salt thereof.

16. The compound of claim 1 , wherein the compound is of formula (IX):

or a pharmaceutically acceptable salt thereof.

17. The compound of claim 1 , wherein the compound is of formula (X):

or a pharmaceutically acceptable salt thereof.

18. The compound of claim 1 , wherein Cy is selected from the group consisting of: